Dyspnea Global Market Report 2025

The dyspnea market size has grown strongly in recent years. It will grow from $6.26 billion in 2024 to $6.75 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to increasing awareness of respiratory diseases, the rising incidence of lifestyle-related factors, the expanding geriatric population, a surge in clinical trials, and growing supportive government initiatives.

The dyspnea market size is expected to see strong growth in the next few years. It will grow to $8.97 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth during the forecast period can be attributed to the increasing prevalence of chronic diseases, rising demand for personalized medicine, worsening pollution levels, greater adoption of telemedicine, and the implementation of more favorable regulations. Key trends in the forecast period include strategic collaborations, technological advancements, the development of novel inhalers, the expansion of personalized medicine, and the rise of targeted therapies.

The rising prevalence of respiratory diseases is expected to drive the growth of the dyspnea market in the coming years. Respiratory diseases affect the lungs and other parts of the respiratory system, leading to difficulty in breathing and impaired oxygen exchange. Common conditions include asthma, chronic obstructive pulmonary disease (COPD), and tuberculosis (TB). The increase in respiratory diseases is attributed to factors such as air pollution, smoking, exposure to environmental toxins, and climate change. Dyspnea plays a key role in diagnosing and managing respiratory conditions by indicating lung function impairment, guiding treatment strategies, and monitoring disease progression. For example, in November 2023, the National Asthma Council, an Australia-based non-profit organization, reported that in 2022, Australia recorded 467 asthma-related deaths, an increase from 355 deaths in 2021 including 299 females and 168 males. As a result, the growing prevalence of respiratory diseases is fueling the expansion of the dyspnea market.

The rise in healthcare expenditure is another key factor contributing to the growth of the dyspnea market. Healthcare expenditure encompasses total financial resources spent on medical services, including public and private spending on hospital care, pharmaceuticals, and preventive treatments. The increasing healthcare expenditure is driven by the rising demand for advanced medical treatments, an aging population, and the growing burden of chronic diseases that require long-term care and costly interventions. Higher investments facilitate the development and accessibility of novel therapies, such as inhalers, oxygen therapy, and biologics, leading to improved patient outcomes. Additionally, increased spending enhances healthcare infrastructure and specialized care, enabling early diagnosis and effective management of dyspnea-related conditions. For instance, in December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% growth recorded in 2021. Consequently, rising healthcare expenditure is supporting the growth of the dyspnea market.

Leading companies in the dyspnea market are focusing on the development of innovative treatments, such as phosphodiesterase (PDE) inhibitors, to enhance therapeutic efficacy and provide improved relief for patients with respiratory conditions. PDE inhibitors work by blocking the activity of phosphodiesterase enzymes, increasing cyclic AMP or cyclic GMP levels in cells, which can enhance vasodilation, reduce inflammation, or improve cardiac function. For example, in May 2024, Verona Pharma Plc, a UK-based biopharmaceutical company, announced its plans for the anticipated U.S. launch of ensifentrine, a first-in-class dual PDE 3/4 inhibitor for COPD treatment, in Q3 2024, pending FDA approval. Ensifentrine, a nebulized treatment for COPD, has demonstrated significant reductions in exacerbation rates and improvements in dyspnea in Phase III clinical trials. The company has secured $650 million in financing to support the drug’s commercial launch and ongoing development, including a planned Phase II trial for a fixed-dose combination with glycopyrrolate as a maintenance therapy for COPD patients.

Major players in the dyspnea market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca, Novartis AG, GlaxoSmithKline, Amgen Inc., Viatris Inc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Amneal Pharmaceuticals LLC, Lupin Ltd, Lincare Holdings Inc, Nephron Pharmaceuticals Corporation, Rotech Healthcare Inc., Inogen Inc, Lannett Inc., Ligand Pharmaceuticals Incorporated, OMRON Healthcare Inc, Flexicare Medical Ltd, Zydus Cadila Healthcare Ltd, Advacare Pharma, Airways surgical Pvt. Ltd., Belluscura Plc.

North America was the largest region in the dyspnea market in 2024. Asia pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dyspnea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dyspnea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dyspnea refers to difficulty breathing or shortness of breath, describing the sensation of not getting enough air into the lungs. It can present as chest tightness, gasping for air, or increased effort to breathe. Various clinical methods and tools are used to assess its severity, impact on daily life, and underlying causes.

The primary treatment options for dyspnea include supplemental oxygen therapy and relaxation therapy. Supplemental oxygen therapy involves delivering oxygen to improve blood oxygen levels, assisting patients with respiratory conditions or those recovering from severe illnesses. The drug classes used for treatment include anti-anxiety medications, antibiotics, anticholinergic agents, corticosteroids, and others. These medications are administered through various routes, such as oral, inhalation, and other methods. Dyspnea treatments are utilized across different healthcare settings, including hospitals, home care, specialty clinics, ambulatory services, and other medical facilities.

The dyspnea market research report is one of a series of new reports that provides dyspnea market statistics, including the dyspnea industry global market size, regional shares, competitors with the dyspnea market share, detailed dyspnea market segments, market trends, and opportunities, and any further data you may need to thrive in the dyspnea industry. This dyspnea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dyspnea market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, oxygen therapy, respiratory monitoring, telemedicine consultations, and patient education programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The dyspnea market also includes sales of products such as bronchodilators, ventilators, nebulizers, portable oxygen concentrators, and pulmonary function testing devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The IT market is segmented into IT services, computer hardware, telecom, and software products.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption. values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.